Medtech Veteran Brian Fahey Joins Board to Steer Novel Heart Failure Tech

LONDON, UK – June 03, 2026 – In a move that signals a significant shift from research and development toward commercial reality, Precision Cardiovascular has appointed seasoned medtech entrepreneur Brian Fahey, Ph.D., to its Board of Directors. For a company developing a novel remote monitoring system for heart failure, this appointment is more than a routine personnel announcement; it's a strategic maneuver aimed at navigating the treacherous path from a groundbreaking concept to a market-ready medical device.

Precision Cardiovascular is at a critical juncture. The London-based innovator is advancing its implantable surface acoustic wave (SAW) sensor technology toward first-in-human studies. Bringing in a figure like Dr. Fahey, whose career is a highlight reel of building, funding, and successfully exiting highly regulated medical device companies, provides a jolt of experience precisely when it's needed most. His track record includes founding two successful companies—Niveus Medical, acquired by Stryker, and Adona Medical, which raised nearly $100 million in institutional capital for its own advanced heart failure solution.

"Welcoming Brian to our Board comes at a defining moment for Precision Cardiovascular as we advance toward first-in-human studies," said Mohamed Abou-Alam, CEO of Precision Cardiovascular. "His experience guiding early-stage cardiovascular innovations will be invaluable as we move from engineering milestones to evaluation in patients and prepare for upcoming financing and execution phases."

A Strategic Play in a Crowded Field

The remote heart failure monitoring market is not for the faint of heart. It's a space dominated by medtech giants like Abbott, whose CardioMEMS HF System is already an established implantable solution for monitoring pulmonary artery pressure. Similarly, Boston Scientific’s HeartLogic™ diagnostic, integrated into its defibrillators, uses a suite of sensors to provide early warnings of worsening heart failure. For an emerging company like Precision Cardiovascular, differentiation is key to survival and success.

This is where the strategic value of Dr. Fahey's appointment becomes clear. His background is steeped in developing and commercializing Class III implantable devices—the most stringently regulated category of medical technology. His leadership at Adona Medical, which developed an implantable shunt with integrated pressure monitoring for heart failure, provides directly relevant experience. He understands the competitive pressures and the clinical and commercial benchmarks that must be met to convince both physicians and investors.

By adding Dr. Fahey to its board, Precision Cardiovascular is broadcasting its intent to compete at the highest level. His presence provides a layer of credibility that is crucial for a company preparing for significant financing rounds needed to fund expensive clinical trials and scale manufacturing. It tells the market that the company's technology is not just an academic exercise but a viable commercial asset being guided by a proven winner.

The Promise of SAW and AI in Precision Medicine

At the core of the company's strategy is its unique technological approach. Precision Cardiovascular is developing a system based on implantable Surface Acoustic Wave (SAW) sensors. These miniature devices operate on a fascinating principle, converting electronic signals into acoustic waves that travel along the surface of a piezoelectric material. Changes in the surrounding physical environment, such as pressure, alter these waves in a measurable way, allowing for highly sensitive and continuous monitoring.

A key advantage of SAW technology is its potential for passive, wireless operation. This means the implantable sensor may not require an internal battery, a major hurdle for long-term implantable devices. By eliminating the need for battery replacement surgeries, such a device could offer a significant improvement in patient safety and convenience, all while being small enough for minimally invasive implantation. This technological edge is what the firm hopes will set it apart from existing solutions.

However, the sensor is only half of the equation. As Dr. Fahey noted in his statement, the company's vision aligns with a future where "AI tools can augment traditional approaches to finally deliver upon the promise of patient-specific, precision medicine care models." The continuous stream of high-fidelity data from the SAW sensor is designed to be fed into sophisticated machine learning algorithms. The goal is to move beyond simple alerts to generate predictive insights, identifying subtle patterns that signal a patient's decline long before symptoms appear. This AI-driven, proactive approach could enable clinicians to intervene earlier and tailor treatments with a level of personalization that is currently out of reach.

Navigating the Gauntlet of Regulatory Approval

An innovative idea, no matter how promising, is worthless without regulatory approval. For a Class III implantable cardiac device, the path to market is a multi-year, multi-million-dollar marathon. In the United States, it involves securing an Investigational Device Exemption (IDE) from the FDA just to begin human trials, followed by extensive pivotal studies to prove safety and effectiveness, all culminating in a rigorous Premarket Approval (PMA) application. The European Union's Medical Device Regulation (MDR) presents a similarly demanding pathway.

This is where Dr. Fahey's experience becomes mission-critical. He has successfully navigated this gauntlet before. At Niveus Medical, he guided a novel muscle stimulation device from concept to FDA clearance and commercial use in over 10,000 treatments before its acquisition. His tenure at Adona Medical involved steering a complex Class III heart failure device through its development and financing stages. This hands-on experience in clinical strategy, regulatory submissions, and quality systems for high-risk devices is an invaluable asset.

As CEO Mohamed Abou-Alam stated, Dr. Fahey's perspective will help the company pursue its opportunity with "rigor, urgency, and a clear focus on patient impact." This rigor is essential for building the mountain of evidence required by regulators, while urgency is needed to maintain a competitive edge and deliver value to investors. His expertise will be instrumental in designing clinical trials that not only meet regulatory requirements but also demonstrate clear clinical and economic benefits, paving the way for eventual physician adoption and reimbursement.

The 'Fahey Effect': A Magnet for Talent and Capital

Bringing a veteran founder like Brian Fahey onto the board creates a ripple effect that extends beyond strategic guidance. His endorsement acts as a powerful validation of Precision Cardiovascular's technology and team. Dr. Fahey, an alumnus of the prestigious Stanford Biodesign Innovation Fellowship with a Ph.D. in Biomedical Engineering from Duke, has a reputation for identifying and building ventures with high potential. His decision to join the board is a vote of confidence that will be noticed by other industry experts, potential partners, and top-tier talent.

Furthermore, his deep connections within the venture capital community and the corporate strategic landscape—honed through roles at Johnson & Johnson and as an Executive in Residence at the medtech incubator Shifamed—are indispensable. As Precision Cardiovascular prepares for its next financing phases, Dr. Fahey’s network and his credibility with investors who understand the risks and rewards of medtech will be a significant advantage.

Ultimately, this appointment is a story about assembling the right team for the right challenge. Precision Cardiovascular has ambitious goals to redefine a complex area of medicine. By adding a director who has not only envisioned the future of medtech but has actively built it, the company has substantially increased its chances of turning that vision into a reality that impacts patients' lives.